Vmbook Online ordering
Biotechnology
XNCR stands for the stock symbol "Xencor, Inc." A biotech company focusing on creating new medicines that utilize thebody's immune system to treat various conditions, including cancer and autoimmune illnesses, is named Xencor, Inc. The business is listed on the Nasdaq stock exchange and trades under the ticker XNCR.
In terms of earnings, Xencor Inc reported a net loss of $51.4 million in its most recent quarter in May 2023. The company's revenue for the quarter was $4.3 million, a 36% decrease from the same period the previous year. The corporation is still in the stages of clinical trials for its medicines and has yet to record a profit.
In terms of growth, Xencor, Inc has been expanding its pipeline of medicines in development and partnerships with other biotech and pharmaceuti companies. For instance, the business announced a licensing agreement with Amgen worth up to $2.5 billion in March 2023. Under the terms of the arrangement, Xencor will create and provide Amgen with an 17 bispecific antibody designed to treat cancer.
In addition, Xenocl's lead drug prospect, plamalizumab, is being studied in multiple clinical trials for treating cancer and autoimmune illnesses. The business is also growing its earlier stage product portfolio, including several bispecific antibodies and T-cell engagers, created using its technology.
Xencor Inc. has also expanded its connections with significant biotech and pharmaceutical businesses, such as Amgen, Merck, and Roche. These collaborations have offered Xencor funding and the chance to work on creating new drugs targeting various disorders.
Xencor, Inc. is a biotechnology company that develops new medicines to treat cancer and autoimmune diseases by leveraging the strength of the immune system. The company is listed on the Nasdaq stock exchange under the ticker symbol XNCR.
In terms of growth, Xencor, Inc has been expanding its pipeline of medicines in development and partnerships with other biotech and pharmaceutical companies. For instance, the business announced a licensing agreement with Amgen worth up to $2.5 billion in March 2023. Under the terms of the arrangement, Xencor will create and provide Amgen with an 17 bispecific antibody designed to treat cancer.
Xencor, Inc. is a biotechnology business that develops new drugs to treat cancer and autoimmune illnesses by harnessing the immune system's strength. The company is listed on the Nasdaq stock exchange under the ticker symbol XNCR.
Xencor's lead therapeutic prospect, plamalizumab, is being tested in clinical trials for malignant and autoimmune diseases. The business is also growing its earlier stage product portfolio, including several bispecific antibodies and T-cell engagers created using its technology.
Xecor Inc. has announced several collaborations with important biotech and pharmaceutical businesses, like Amgen, Merck, and Roche. These collaborations have allowed Xencor to fund its operations and work on creating new drugs that target various conditions.
Regarding financials, Xencor, Inc. reported a net loss of USD 51.4 million in its most recent quarter in May 2023. The company's revenue for the quarter was USD 4.3 million, a decrease of 36% from the same period the previous year. The corporation is still in the clinical trials stage with its medications and has yet to record a profit.
Xencor, INC. was founded in 2000 and has its headquarters in Monrovia, California. It is a public business listed on the Nasdaq market under the ticker symbol "XNCR." Xencor, Inc. is a biotechnology company that develops new medicines that utilize the immune system's power to treat cancer and autoimmune illnesses. The company is listed on the Nasdaq stock exchange under the ticker symbol XNCR.